Pfizer (PFE) is collaborating with Atavistik Bio to accelerate the discovery of new precision allosteric therapeutics, Atavistik said Thursday.
Financial terms of the partnership were not disclosed.
Under the research partnership, the companies will use Atavistik's AMPS platform to identify allosteric binders against two undisclosed targets picked by Pfizer, according to Atavistik.
The collaboration grants Pfizer the option to license the programs at the end of the research period, Atavistik added.
Price: 26.61, Change: +0.08, Percent Change: +0.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.